Skip to content
MARKETS / NYSE / CPHI
NYSE · PHARMACEUTICAL PREPARATIONS · SMALL CAP

China Pharma Holdings, Inc. CPHI

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$4.1M
▼ 8.5% YoY
$-3.2M
$88,937
In brief

What this company does

China Pharma is not a Chinese operating company and all the operations are conducted by our wholly owned subsidiary, Hainan Helpson Medical and Biotechnology Co., Ltd. (“Helpson”) and Helpson’s subsidiaries in China. We, through Helpson, are principally engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People’s Republic of China (the “PRC”). Helpson manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. As of December 31, 2025, China Pharma, through Helpson, is granted rights to manufacture for 19 pharmaceutical products for a wide variety of diseases and medical indications, each of which may be classified into one of three general categories: China Pharma, through Helpson, currently own and operate two production facilities in Haikou, Hainan Province, PRC.

Written from the business description in China Pharma Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 1 April 2026. Every sentence was checked against that document before publication.

Growth
USD 4.1M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 4.1 · Net income -3.2
40M80M-20M201020122014201620182020202220242025
Compound annual growth
−20.0%
−17.5%
−14.7%
−17.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −17.5% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−77 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -78.2% · Net -76.9%
10%20%30%-50%-100%-150%201020122014201620182020202220242025
ROE
FY2025 · ROE -20.9%
5%10%15%-50%-100%201020122014201620182020202220242025

Each USD of equity lost 21 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 0.1
10M20M201020122014201620182020202220242025

Total assetsUSD 31.0M
EquityUSD 22.7M
CashUSD 345,112.00
Gross debtUSD 1.4M
Net debtUSD 1.1M
Current ratio0.32×

Net debt stands at 5% of equity.

The 16-year record
16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.10.10.1
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.00.00.0
EBITDA $B−0.0−0.00.0−0.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.00.00.0
Income tax $B·······−0.00.00.00.0−0.0−0.0−0.0−0.0−0.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.00.00.0
Free cash flow $B0.0−0.0−0.0−0.0−0.0−0.00.00.00.00.00.00.00.00.00.00.0
EPS, diluted $−0.74−2.71−0.91−3.78−0.74−0.07−0.48−0.25−0.44−0.21−0.35−0.91−0.460.110.440.54
Dividend / sh $················
Payout %················
ROE %−20.9−62.3−52.4−77.1−48.5−33.3−105.0−29.3−37.8−14.0−18.6−35.0−14.23.214.819.9
Shares out B0.020.000.010.000.000.050.040.040.040.040.040.040.040.040.040.04

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures · 4 divergences in 77 reconciliationsAUDITED

Reconciled in 12 of 19 fiscal years. 4 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 18 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures4 divergent
ActivityPharmaceutical Preparations
Listed onNYSE
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image